Targeted peptides are short chains of amino acids studied for their role in cell signaling, in contrast to bulk protein, which supplies amino acids as raw material. This post is for athletes, active adults, and evidence-focused shoppers who want to understand what the research on peptides covers and what it does not. Claims supported by published research are kept separate from marketing claims, and the limits of the evidence are stated alongside the findings. Much of the published work on peptides comes from cell and animal models, and much of the human work involves different peptides than the ones in any single supplement, so each source below is described by what it actually studied. Pürblack’s peptides are oral, natural, and taken as capsules. The post notes where a finding applies to them and where it does not. The final section gives a checklist for evaluating any peptide supplier, followed by how Pürblack approaches the same criteria.
How targeted peptides relate to energy and performance
Cells produce most of their energy in mitochondria, and a growing body of research looks at how peptides take part in the signaling that coordinates that process. A 2020 review in the American Journal of Physiology–Endocrinology and Metabolism describes mitochondrial-derived peptides, small peptides encoded in mitochondrial DNA, including humanin and MOTS-c. According to the review, circulating levels of these peptides are lower with aging and in some metabolic conditions, while their expression in muscle rises in response to stressors such as exercise. In rodents, treatment with several of them improved insulin sensitivity. The authors state that whether these properties can be turned into therapies has yet to be determined.
Two limits apply. These are peptides the body makes itself, studied largely in cells and rodents, and the review does not evaluate peptides taken orally as supplements.
For IPH-AGAA, the ingredient in Muscle+, the available mechanistic data come from cell culture. In a 2019 report using cells derived from human embryonic muscle, IPH-AGAA at 20 ng/ml was associated with higher expression of Myf5, a regulator of muscle cell differentiation (about 2.9-fold versus control), and of the proliferation markers Pax7 and Ki67 (about 1.2-fold each), and with lower expression of the apoptosis marker p53 (about 1.6-fold lower) [Roitman et al.]. The authors note the effects may reflect the embryonic origin of the cells. These are laboratory findings in one cell model and do not show an effect in people taking the supplement. The IPH peptide family was developed at the St. Petersburg Institute of Bioregulation and Gerontology and is commercialized by Ideal Pharma Peptide GmbH, whose staff co-authored this report. The IPH studies cited in this post come from overlapping author groups and were published in journals with limited indexing, and independent replication has not been published.
Readers searching for high-potency peptides for sustained energy, or asking which natural peptide to buy for performance, will find that the research does not define potency for oral peptide supplements or rank products against each other. What can be checked is what a supplier discloses: the peptide identified by name or sequence, the amount per serving, and whether an independent laboratory has verified the contents. The checklist below covers each.
Peptides and exercise recovery
The most substantial human evidence on peptide supplementation and recovery involves collagen peptides, a different class from the short signaling peptides above. A 2024 systematic review and meta-analysis in Sports Medicine pooled 19 randomized controlled trials with 768 healthy adults. It found a statistically significant effect of collagen peptides on recovery of reactive strength 48 hours after exercise-induced muscle damage (standardized mean difference 0.43, p = 0.045). The authors rated the certainty of evidence as low to very low for most outcomes, including recovery, and moderate for body composition. A 2021 systematic review in Amino Acids of 15 randomized trials, 12 of them in recreational athletes, reported some improvements in muscle recovery. It concluded that the mechanisms are unclear and that larger studies with more precise measures are needed.
Two studies of the ingredient IPH-AGAA were reported in one 2019 paper in the Österreichisches Multiscience Journal [Ivko et al.]. In a rat model of notexin-induced muscle injury (40 aged rats, 20 per group), animals given IPH-AGAA orally for 14 days had lower blood levels of the inflammatory markers TNF-α and IL-1β, higher IL-10, and a larger area of restored muscle fiber on histology (89.4% versus 36.8%). In the same paper, 77 men aged 30 to 58 took 100 µg of IPH-AGAA daily in three 30-day courses separated by 30-day breaks. At 3 and 6 months they reported higher activity, energy, and endurance scores than at baseline, with higher measured muscle mass and a higher dynamometer strength index. A 50 µg group showed no change, and 150 µg did no better than 100 µg. The human study had no placebo group, reported no blinding, and relied partly on self-ratings and a consumer body-composition scale. Results were compared with baseline and across the three dose levels, so the study cannot show that the peptide caused the changes. The paper does not report adverse events or safety monitoring.
The studied dose does not match the product. The study used 100 µg of IPH-AGAA per day. Muscle+ provides 50 mg of IPH AGAA peptide complex per two-capsule serving. The label lists 1% of that complex, about 0.5 mg (500 µg), as the named tetrapeptide. Neither paper gives the peptide’s sequence or composition, so the link between the studied material and the Muscle+ ingredient rests on Pürblack’s identification of the complex as IPH AGAA. The label suggests 1 to 3 servings daily with no off-cycles, where the study used 30-day courses with 30-day breaks. Muscle+ also contains about 940 mg of branched-chain amino acids, which were not part of the studies. These findings describe the ingredient under the study’s conditions and are not claims about Muscle+.
On safety, two randomized, double-blind, placebo-controlled trials of oral low-molecular-weight collagen peptides in healthy adults reported no adverse events. One was a 12-week trial of 100 participants that included serial blood tests. The other was an 8-week trial of 70 participants. Both measured skin outcomes rather than exercise outcomes, and neither speaks to peptides other than collagen peptides or to use beyond a few months. Doses and peptide types in these studies differ from those in any Pürblack product, so the findings are context, not claims about Pürblack products. Safety data specific to IPH-AGAA were not reported in the studies reviewed here.
How to choose a trusted peptide supplier
Four checks apply to any peptide supplier.
Third-party testing. Look for testing by a laboratory independent of the manufacturer, and check what it tested. Contaminant screening and identity or composition testing are different checks, and they are sometimes performed by different parties.
Published certificates of analysis. A certificate of analysis should be available for the product you are buying, show the batch number, name the laboratory, and report actual results rather than a pass badge.
Manufacturing transparency. The supplier should state where and how the product is made, and the label should name each peptide and its amount, including what share of a blended complex the named peptide represents.
Published research. Look for peer-reviewed studies on the ingredient, with sample size, design, and dose stated, and check whether the study tested the ingredient in the product or a different peptide.
Pürblack’s approach, in the company’s own words: its peptides are oral, natural, marine-derived, and made in the USA. Muscle+ and Joint+ are NSF Certified for Sport®. Every peptide product has two certificates of analysis published on the company’s COA page, one issued by NSF covering heavy metals, microbial testing, and purity, and one internal covering identity and composition. The Muscle+ label lists its peptide complex (IPH AGAA, 50 mg per two-capsule serving), the complex’s composition (60% protein, 1% of the named tetrapeptide, 39% free amino acids), and the amount of each branched-chain amino acid. The company describes the research on its ingredients as preclinical and early clinical, from author groups connected to the ingredient’s developer, with no independent replication published to date. It holds seven granted U.S. patents covering shilajit processing, purification, formulation, and dispensing devices. Patents describe technology and are not evidence of product efficacy.
Closing
Evaluating a peptide supplement comes down to a few questions: what was studied, at what dose, in whom, and for how long; whether an independent lab has tested the product and the results can be read; whether the manufacturer explains how and where it is made; and whether the supporting research is published and specific to the ingredient. The research on peptides and recovery is promising in places and early in others, and no supplement replaces training, sleep, and nutrition. This article is for general information and is not medical advice. Check with a clinician before starting any supplement, especially if you take medication or have a medical condition.
Sources retrieved from PubMed: Merry et al., Am J Physiol Endocrinol Metab 2020 (DOI); Bischof et al., Sports Med 2024 (DOI); Khatri et al., Amino Acids 2021 (DOI); Kim et al., J Med Food 2022 (DOI); Lee et al., J Microbiol Biotechnol 2025 (DOI). Ingredient studies: Ivko et al., Österreichisches Multiscience Journal No. 19, 2019, pp. 15–22; Roitman R. et al., “The Effect of the Peptide IPH-AGAA on the Proliferation of Muscle Cells of Human,” 2019.
